Genomic & Biopharma NewsRobotic exoskeleton offers potential new approach to alleviating crouch gait in children with cerebral palsy
This study is the first step toward the long-term goal of implementing a novel device-based approach to treating crouch gait.
|National Institutes of Health, 2017-08-25 18:15:00|
Labs in Texas Batten Down the Hatches
As Hurricane Harvey approaches land, researchers wait to see if their preparations will protect their experiments.
|The Scientist, 2017-08-25 16:00:00|
Insights into fat signaling could boost the fight against obesity and diabetes
Natriuretic peptides, or NPs, send signals in adipose tissue that can turn harmful white fat into energy-burning brown fat. But NP signaling may have an even broader role in protecting against metabolic disease.
|Fierce Biotech, 2017-08-25 15:38:37|
Adamas scores orphan approval for tweaked generic Parkinson's medication
Adamas may be the first company to have won FDA approval for a medication to treat dyskinesia in Parkinson’s patients. But that doesn’t mean it will be the first company to use that med to treat the condition.
|Fierce Pharma, 2017-08-25 15:37:10|
News of Note—Cancer diagnostics startup Celcuity files for $15M IPO
Here's Friday's medtech news of note.
|Fierce Biotech, 2017-08-25 15:34:28|
Exosome Diagnostics, CareFirst partner to speed up coverage for diagnostic tests
Liquid biopsy player Exosome Diagnostics is partnering with CareFirst to create evidence development studies for the evaluation of its EvoDx tests.
|Fierce Biotech, 2017-08-25 15:08:46|
Exosomes as Reconfigurable Therapeutic Systems
Historically, small molecules, including steroid hormones and cytokines, have been attributed a role in paracrine and endocrine signaling, and now include a new player: biological nanoparticles, or ‘exosomes’. Generated intracellularly, and defined simply as nanoparticulate packages of signaling moieties, exosomes have emerged as vehicles for highly specialized local and distant intercellular communication. Exosomes are increasingly ...
|Exosome RNA Research & Industry News, 2017-08-25 14:55:06|
Fund's $80B Valeant losses prompt lawsuit calling company a criminal enterprise
A mutual fund that claims it lost a mind-boggling $80 billion on its Valeant investments has rolled a long list of alleged violations into a lawsuit that alleges Valeant was a criminal enterprise.
|Fierce Pharma, 2017-08-25 14:54:00|
NICE flip-flops on Takeda's Adcetris—with restrictions
Takeda has scored a victory in its quest to secure reimbursement in England for lymphoma med Adcetris. But it’s only a partial victory.
|Fierce Pharma, 2017-08-25 14:43:17|